Fractyl Health, Inc. GUTS 深 滬
已收盤 10-31 16:00:00 美东时间
1.23
0.000
0.00%
華盛通- 最 高1.27
- 今 開1.23
- 成交量 129.27万股
- 最 低 1.2101
- 昨 收 1.23
- 總市值 6185.55万
- 52周最高 3.03
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.825
- 委 比 35.46%
- 總股本 5028.90万
- 歷史最高 14.50
- 量 比 1.03
- 振 幅 4.87%
- 歷史最低 0.825
- 每 手 1
- 風險率 0.46%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, Oct. 21, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – Conventional small molecule approaches hav...
10-21 21:20
Fractyl Health Unveils Preclinical Results for RJVA-002, Showing 30% Weight Loss in Obesity Model
Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced potent new
10-07 19:12
Fractyl Health Announces Potent Preclinical Results from RJVA-002, a Dual GIP/GLP-1 Gene Therapy Candidate for Obesity
Fractyl Health announced potent preclinical data for RJVA-002, a gene therapy targeting obesity, showing ~30% weight loss in 5 weeks in a translational obesity model. This dual GIP/GLP-1 therapy demonstrates significant and durable efficacy, potentially rivaling chronic drug treatments. The company aims to expand its Rejuva platform beyond T2D to obesity, highlighting a novel approach for durable weight loss through a single administration.
10-07 11:00
美股大行评级 | 潜在涨幅485.44%！Allarity Therapeutics获机构升目标价至9.25美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持Allarity Therapeutics"买入"评级，目标价从9美元升至9.25美元；JMP证券：维持Crinetics Pharmaceuticals"跑赢大市"评级，目标价从86美元升至143美元
09-29 09:15
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
09-26 20:10
Fractyl Health Reveals Promising REMAIN-1 Study Results
The latest update is out from Fractyl Health, Inc. ( ($GUTS) ). On September 26...
09-26 19:28
Fractyl Health Study Shows Revita Helps Prevent Weight Regain After Stopping Popular GLP-1 Drugs
Fractyl Health, Inc.
09-26 19:01
Fractyl Health Announces Groundbreaking Data from REMAIN-1 Midpoint Cohort Showing Revita® Maintained Weight Loss After GLP-1 Discontinuation
Fractyl Health announced positive results from the REMAIN-1 Midpoint Cohort study, showing that Revita, an endoscopic duodenal mucosal resurfacing procedure, helped patients lose an additional 2.5% of body weight after stopping GLP-1 drugs, while sham-treated patients regained 10%. The study met its 3-month efficacy endpoint with strong statistical significance (p=0.014) and demonstrated excellent safety and tolerability. These findings suggest R...
09-26 11:00
美股大行评级 | 潜在涨幅432.99%！维持"投机性买入"评级，Unicycive Therapeutics获机构升目标价至21美元
今日重点评级关注：Benchmark：维持Unicycive Therapeutics"投机性买入"评级，目标价从3美元升至21美元；Guggenheim：维持Amylyx Pharmaceuticals"买入"评级，目标价从17美元升至25美元
09-16 09:48
HC Wainwright & Co. Initiates Coverage On Fractyl Health with Buy Rating, Announces Price Target of $9
HC Wainwright & Co. analyst Joseph Pantginis initiates coverage on Fractyl Health (NASDAQ:GUTS) with a Buy rating and announces Price Target of $9.
09-15 19:15
